EGFR-IN-175

EGFR-IN-175 is an orally active and selective EGFRL858R/T790M/C797S inhibitor with an IC50 of 18.94 nM. EGFR-IN-175 can induce cell apoptosis and cause G1 phase arrest. EGFR-IN-175 can downregulate p-EGFR, p-AKT, and p-ERK expression. EGFR-IN-175 can be used for the research of cancer, such as lung cancer[1].

Product Specifications

UNSPSC

12352005

Target

Akt; Apoptosis; EGFR; PERK

Related Pathways

Apoptosis; Cell Cycle/DNA Damage; JAK/STAT Signaling; PI3K/Akt/mTOR; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Smiles

O=C1C(C2=CC=CS2)=NC3=CN=C(NC4=CC=C(N5CCC(N6CCN(C)CC6)CC5)C=C4)N=C3N1C7=CN(S(=O)(C8CC8)=O)N=C7OC

Molecular Formula

C33H38N10O4S2

Molecular Weight

702.85

References & Citations

[1]Jiang W, et al. Direct Ser797 Interacted Pteridine-7 (8H) -one Derivatives as Highly Selective and Orally Available EGFRL858R/T790M/C797S Inhibitors. J Med Chem. 2025 Sep 11;68 (17) :18463-18490.